Table 2.
Drug Pairs Meeting Synergy Criteria in the First Synergy Test (Matrix 1) Against Ebola Virus Infection in Vitro
| Drug 1 | Drug 2 | Synergy Metric | |||
|---|---|---|---|---|---|
| Excess HSA | Beta | Gamma | DBSumNeg | ||
| Clomiphene | Sertraline | -624.87914 | 0.72461 | 0.70293 | -5.47307 |
| Clomiphene | Apilimod | -611.45525 | 0.81777 | 0.7437 | -4.90124 |
| Sertraline | Toremifene | -508.27371 | 0.71123 | 0.67734 | -4.40112 |
| Toremifene | Apilimod | -534.71687 | 0.7834 | 0.72715 | -4.35384 |
| Colchicine | Sertraline | -650.30131 | 0.81128 | 0.68203 | -4.14049 |
| Clomiphene | Colchicine | -517.9869 | 0.83442 | 0.74282 | -3.52601 |
| Colchicine | Sunitinib | -432.75556 | 0.85566 | 0.75889 | -2.92912 |
| Colchicine | 3-Deazaneplanocin A | -634.77105 | 0.87178 | 0.62148 | -2.71511 |
| Colchicine | Toremifene | -465.88398 | 0.84175 | 0.71685 | -2.61726 |
The synergy criteria imposed were as follows: Excess HAS, less than -400; Beta, <0.9; Gamma, <0.8; and DBSumNeg, less than -2. See Results for a description of the 4 synergy metrics and the Supplementary Methods for details on experimental design and synergy metrics.